Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2005 Dec 6;143(11):793-7.
doi: 10.7326/0003-4819-143-11-200512060-00007.

Treatment of lateral epicondylitis with botulinum toxin: a randomized, double-blind, placebo-controlled trial

Affiliations
Randomized Controlled Trial

Treatment of lateral epicondylitis with botulinum toxin: a randomized, double-blind, placebo-controlled trial

Shiu Man Wong et al. Ann Intern Med. .

Abstract

Background: Lateral epicondylitis is a common condition for which botulinum toxin has been reported to have a therapeutic role in uncontrolled studies.

Objective: To determine if an injection of botulinum toxin is more effective than placebo for reducing pain in adults with lateral epicondylitis.

Design: Randomized, double-blind, placebo-controlled trial conducted from September 2002 to December 2004.

Setting: Outpatient clinics at a university hospital and a district hospital in Hong Kong.

Participants: 60 patients with lateral epicondylitis.

Measurements: The primary outcome was change in subjective pain as measured by a 100-mm visual analogue scale (VAS) ranging from 0 (no pain) to 10 (worst pain ever) at 4 weeks and 12 weeks. All patients completed post-treatment follow-up.

Interventions: A single injection of 60 units of botulinum toxin type A or normal saline placebo.

Results: Mean VAS scores for the botulinum group at baseline and at 4 weeks were 65.5 mm and 25.3 mm, respectively; respective scores for the placebo group were 66.2 mm and 50.5 mm (between-group difference of changes, 24.4 mm [95% CI, 13.0 to 35.8 mm]; P < 0.001). At week 12, mean VAS scores were 23.5 mm for the botulinum group and 43.5 mm for the placebo group (between-group difference of changes, 19.3 mm [CI, 5.6 to 32.9 mm]; P = 0.006). Grip strength was not statistically significantly different between groups at any time. Mild paresis of the fingers occurred in 4 patients in the botulinum group at 4 weeks. One patient's symptoms persisted until week 12, whereas none of the patients receiving placebo had the same complaint. At 4 weeks, 10 patients in the botulinum group and 6 patients in the placebo group experienced weak finger extension on the same side as the injection site.

Limitations: The trial was small, and most participants were women. The blinding protocol may have been ineffective because the 4 participants who experienced paresis of the fingers could have correctly assumed that they received an active treatment.

Conclusions: Botulinum toxin injection may improve pain over a 3-month period in some patients with lateral epicondylitis, but injections may be associated with digit paresis and weakness of finger extension.

Trial registration: ClinicalTrials.gov NCT00119704.

PubMed Disclaimer

Comment in

  • The myriad uses of botulinum toxin.
    Pullman SL. Pullman SL. Ann Intern Med. 2005 Dec 6;143(11):838-9. doi: 10.7326/0003-4819-143-11-200512060-00014. Ann Intern Med. 2005. PMID: 16330797 No abstract available.

Summary for patients in

Publication types

Substances

Associated data